Disturbed angiogenesis in systemic sclerosis: High levels of soluble endoglin

Rheumatology

Volumn 47, Issue 7, 2008, Pages 972-975

  Wipff, J ^a,b   Avouac, J ^a,b   Borderie, D ^c   Zerkak, D ^a   Lemarechal, H ^c   Kahan, A ^a   Boileau, C ^b,d   Allanore, Yannick ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c A Paré Hospital ^*  (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Asymmetric dimethylarginine; Soluble endoglin; Soluble vascular endothelial growth factor; Systemic sclerosis

Indexed keywords

BIOLOGICAL MARKER; CARBON MONOXIDE; ENDOGLIN; N(G),N(G) DIMETHYLARGININE; VASCULOTROPIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG DIFFUSION CAPACITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SKIN ULCER; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIGENS, CD; ARGININE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; SCLERODERMA, SYSTEMIC; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45749100869     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken100     Document Type: Article

References (18)

1. Distler O, Distler JH, Scheid A et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004;95:109-16.
2. Distler JH, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology 2006;45(Suppl 3):iIi26-7.
3. Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Arthritis Res Ther 2004;6:R309-14.
4. Distler O, Del Rosso A, Giacomelli R et al. Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002;4:R11.
5. Bobik A. Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 2006;26:1712-20.
6. Venkatesha S, Toporsian M, Lam C et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-9.
7. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
8. Fujimoto M, Hasegawa M, Hamaguchi Y et al. A clue for telangiectasis in systemic sclerosis: Elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease. Dermatology 2006;213:88-92.
9. Wipff J, Kahan A, Hachulla E et al. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology 2007;46:622-5.
10. Andersen GN, Caidahl K, Kazzam E et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: Findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000;43:1085-93.
11. Vallance P, Leiper J. Cardiovascular biology of the asymmetric climethylarginine: Dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-30.
12. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
13. Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
14. Allanore Y, Avouac J, Wipff J, Kahan A. New therapeutic strategies in the management of systemic sclerosis. Expert Opin Pharmacother 2007;8: 607-15.
15. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:134-44.
16. Cudmore M, Ahmad S, Al-Ani B et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007;115: 1789-97.
17. Kikuchi K, Kubo M, Kadono T, Yazawa IN, Ihn H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998; 139: 1049-51.
18. Dooley A, Gao B, Bradley N et al. Abnormal nitric oxide metabolism in systemic sclerosis: Increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology 2006;45:676-84.